ATM in PDAC

Tovecimig plus paclitaxel improved objective response over paclitaxel alone in previously treated advanced biliary tract cancer in COMPANION-002.

Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.

Adding durvalumab and enfortumab vedotin around cystectomy extended survival in muscle-invasive bladder cancer without cisplatin options.

Adding pembrolizumab to adjuvant radiation did not meet prespecified superiority criteria in patients with stage I/II high-intermediate–risk dMMR endometrioid endometrial cancer in the phase 3 NRG-GY020 trial.

Adding tarlatamab-dlle to durvalumab maintenance extended survival in extensive-stage small cell lung cancer in the phase 3 DeLLphi-305 trial.

Adding intismeran autogene to pembrolizumab cut the risk of recurrence and distant metastasis in resected high-risk melanoma in INTerpath-001.

Adding darolutamide to androgen deprivation and primary or salvage radiation lowered metastasis risk in very high-risk localized prostate cancer.

INCA33890 combined with standard-of-care therapy produced responses in first- and third-line metastatic microsatellite stable colorectal cancer.